Início › Câncer de Mama Triplo-Negativo › Massachusetts › Boston
Ensaios clínicos de Câncer de Mama Triplo-Negativo em Boston, MA
26 estudos para Câncer de Mama Triplo-Negativo estão buscando participantes em locais em Boston e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecrutandoFase 1
- Massachusetts General Hospital, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecrutandoFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RecrutandoFase 1
- Dana Farber Cancer Institute, Boston
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
RecrutandoFase 1
- Dana-Farber Cancer Institute, Boston
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RecrutandoFase 3
- Massachusetts General Hospital Cancer Center ( Site 0091), Boston
- Dana Farber Cancer Institute ( Site 0090), Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RecrutandoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer
Recrutando
- Massachusetts General Hospital, Boston
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RecrutandoFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RecrutandoFase 3
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RecrutandoFase 1
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RecrutandoFase 1
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
RecrutandoFase 1
- Dana-Farber Cancer Institute, Boston
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RecrutandoFase 2/3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
RecrutandoFase 2
- Dana-Farber Cancer Institute, Boston
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RecrutandoFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RecrutandoFase 1
- Massachusetts General Hospital, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RecrutandoFase 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Sacituzumab Govitecan In TNBC
RecrutandoFase 2
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
RecrutandoFase 1
- Dana-Farber Cancer Institute, Boston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RecrutandoFase 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4175408 in Participants With Advanced Cancer
RecrutandoFase 1
- Massachusetts General Hospital, Boston
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
RecrutandoFase 2
- Dana-Farber Cancer Institute, Boston
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RecrutandoFase 2
- Dana Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
RecrutandoFase 1
- Dana Farber Cancer Institute, Boston
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
RecrutandoFase 1
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
RecrutandoFase 1/2
- Massachusetts General Hospital, Boston
Ensaios de Câncer de Mama Triplo-Negativo em outras cidades
- Houston, TX42 estudos
- New York City, NY31 estudos
- Nashville, TN28 estudos
- Los Angeles, CA27 estudos
- San Antonio, TX23 estudos
- St. Louis, MO21 estudos
- Arlington, VA20 estudos
- Atlanta, GA20 estudos
- Dallas, TX18 estudos
- Chicago, IL16 estudos
- Columbus, OH16 estudos
- Grand Rapids, MI15 estudos
Outros estudos em Boston
- Câncer de Mama112 estudos
- Câncer de Pulmão de Não Pequenas Células90 estudos
- Câncer (todos os tipos)85 estudos
- Câncer Metastático63 estudos
- Câncer Colorretal63 estudos
- Câncer de Pulmão62 estudos
- Câncer de Ovário61 estudos
- Câncer de Próstata59 estudos
- Depressão52 estudos
- Câncer Endometrial50 estudos
- Insuficiência Cardíaca44 estudos
- Leucemia Mieloide Aguda44 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.